Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 1997

View Archived Issues

Sankyo prepares antifungal agents

Gelatinase inhibitors prepared by Ono

Roussel Uclaf reports agents for BPH

Prostaglandin derivatives from Ono

MMP inhibitors described by Kureha

Merck KGaA's new ET antagonists

Na+/K+-exchange inhibitors from Merck KGaA

Novel LT biosynthesis inhibitor discovered by Abbott

Recombinant human hemoglobin produced by transgenic tobacco

Annual Report: Celltech

Annual Report: Ergo Science

Biogen and CV Therapeutics codevelop cardiovascular therapy

Novo Nordisk characterizes potential antipsychotic agent

Aradigm awarded NIH SBIR grant for respiratory disease therapy

AEterna enters into agreement to finance clinical studies with Neovastat

Successful animal study of PDIT for metastatic breast cancer

P-glycoprotein prevents absorption of saquinavir

Eurand develops taste-masked form of ketoprofen

PDT with Photofrin for early-stage esophageal and lung cancer

Painless local dermal anesthesia now available

Clinical testing of Visualine II tests completed

Cytogen seeks Canadian approval for Quadramet

Lark studies link between cell immortalization and tumor malignancy

Cel-Sci purchases complete rights to Multikine

Atorvastatin approved in Canada

LifeCell reports first sales of Alloderm products

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.